Introduction
============

A number of experimental and clinical studies have provided evidence in support of the neuroprotective effects of induction of hypothermia. The earliest recording of hypothermia as a therapeutic agent is dated more than 5000 years old, coming from an ancient Egyptian Edwin Smith Papyrus ([@B106]). In ancient times, hypothermia therapy consisting of ice packs was used to treat hemorrhage, and said therapy was also widely used in cardiac arrest ([@B20]), comatose patients ([@B15]) and other diseases. There was an apparent interest in the exploration of the mechanism(s) of hypothermia neuroprotection. A role of hypothermia has now been reported in many neurological diseases, for instance, stroke, traumatic brain injury, intracranial pressure elevation, subarachnoid hemorrhage, spinal cord injury, hepatic encephalopathy, and neonatal peripartum encephalopathy ([@B43]). However, it has also been reported that hypothermia may not be neuroprotective ([@B12]; [@B35]; [@B63]). Such discrepancies in literature might perhaps be related to the duration of cooling time and the methods used to induce hypothermia ([@B12]; [@B35]; [@B109]; [@B63]). The methods employed to induce hypothermia have profound effect on the resulting neuroprotection. Combination with other treatment methods has been explored as a means to enhance the benefits of hypothermia protection. Even after several reports on the topic, the mechanisms, by which hypothermia affords neuroprotection, remain unclear. It is believed that hypothermia-induced neuroprotection might be due to decreased metabolism, reduced generation of radicals, ameliorated inflammation and inhibition of excitotoxicity and apoptosis. Further, the importance of cold-induced proteins as important components of hypothermia neuroprotection has also been realized. In this review, we have summarized methods of hypothermia induction, and the effectiveness of combination of other neuroprotective methods with hypothermia and the cold-induced proteins. We hope that this article will provide guidance for future pre-clinical studies and the clinical trials on hypothermia neuroprotection.

Hypothermia Induction Methods
=============================

Experimental as well as clinical data points to a proven neuroprotective effect of therapeutic hypothermia. Also, hypothermia induction methods have an influence on the hypothermia effect. The two most commonly used methods for induction of hypothermia are local hypothermia and general hypothermia.

Local hypothermia provides precise hypothermic regions in the damaged area and the rectal temperature is kept 34--35°C to minimize the potential side effects of hypothermia. Many physical methods are used to achieve local hypothermia, for example, a cooling helmet is a good way to achieve rapid and selective brain hypothermia for a stroke or head injury patient ([@B105]; [@B37]). In a research study comprising of 15 patients following resuscitation, selective head cooling by a cooling helmet decreased urinary 8-OHdG levels on days 6 and 7 ([@B37]). [@B7] used a cooling coil made from silicone tubing in a severe hypoxia model of preterm fetal sheep for local hypothermia and observed reduced loss of neurons and immature oligodendroglia. In a study on spinal cord injury research ([@B6]), the system included a heat exchanger constructed from copper tubing, bent into four layers that were all equal in length, measuring 4.4 × 0.8 inches each, and the tubing was inserted under the skin over the paravertebral muscle extending from the T6 to T10 spinal segments. By circulating cold water, local hypothermia was achieved and was found to be beneficial for spinal cord injury.

In general therapy, a 33--34°C rectal temperature is maintained, creating a moderate systemic hypothermia ([@B91]; [@B4]; [@B39]). Further, for general hypothermia, two approaches commonly used are physical hypothermia and pharmacological hypothermia. Reducing ambient temperature, using a cooling blanket or ice pad and infusing rapidly cooled saline are considered physical hypothermia ([@B37]). Pharmacological hypothermia is related to drugs such as the neurotensin (NT) ([@B121]). [@B29] revealed the potential therapeutic effects on stroke and traumatic brain injury of adult rodents of Neurotensin receptor-1 (NTR1) agonist HPI201 (formerly known as ABS201)-induced hypothermia. HPI201-induced hypothermia resulted in markedly reduced MMP-9 levels and caspase-3 activation. NTR1 agonist induced hypothermia via the NTR receptor in the brain ([@B18]). [@B36] demonstrated that HPI-363 is approximately 10 times more potent than HPI-201 in inducing therapeutic hypothermia. HPI-363 is the analog of NT (8--13). This is because of the C-terminal hexapeptide that has structural elements critical for complete biological activity ([@B9]). The biologically stable NT (8--13) analogs can penetrate the blood--brain barrier ([@B45]), while original NTR1 agonists cannot. Anesthetic is another method used to induce hypothermia ([@B108]). It has been reported that isoflurane-induced hypothermia attenuates the early phase blood-brain barrier disruption in cerebral ischemia ([@B60]). N-cyclohexyladenosine (CHA), an A~1~ adenosine receptor (A~1~AR) agonist, also induced hypothermia, and animals subjected to cardiac arrest and cooled by CHA survived better and exhibited less neuronal cell death ([@B41]). Further, the agonist of transient receptor potential vanilloid channel 1 (TRPV1), dihydrocapsaicin (DHC), is used in pharmacological hypothermia as well ([@B119]). Compared with pharmacological cooling processes, physical cooling processes are costly and time-consuming ([@B1]). It may be because of shivering, a defensive metabolic response to cold, that works against temperature reduction. Therefore, anesthesia has to be used in patients to combat the cold defense response, which has the potential to lead to infection and possibly other side effects due to prolonged hypothermia ([@B89]), while NTR compounds lead to a lack of shivering ([@B29]). Also, physical cooling has associated complications such as hypotension, arrhythmia and change of fluid pH ([@B28]; [@B65]; [@B93]). It seems that pharmacological reagent-induced controlled hypothermia, which targets the brain thermoregulatory center, has emerged as an efficient and considerably safer treatment for patients, with a further benefit being that a lot of choices of drug are provided. [@B121] reviewed the neuroprotective effects of eight classes of hypothermia-inducing drugs: the cannabinoids, opioid receptor activators, transient receptor potential vanilloid, neurotensins, thyroxine derivatives, dopamine receptor activators, hypothermia-inducing gasses, adenosine and adenine nucleotides. However, pharmacological intervention still has its limitations. Just like NT (8--13) analogs, the drugs caused severe hypothermia (\<30 degrees) leading to the requirement for more significant re-warming measures ([@B98],[@B99]; [@B44]; [@B92]). Drugs also have the associated problem of drug resistance and hypothermic tolerance. Every drug application may disturb the balance of whole body such as the metabolic and cardiovascular systems ([@B75]), in addition to the face that each person has individual differences in the drug dose they require. Moreover, it has been demonstrated that the combination of low DHC and ice pads significantly improves every measured outcome, compared to low DHC or the ice pad alone. Combination therapy achieved hypothermia faster; reduced more neurological deficits and decreased apoptotic cell death ([@B119]). [@B5] found that the combination therapy sustained more benefits in late outcome assessment of cerebral hypoxia-ischemia. These observations clearly indicate that combining physical and pharmacological hypothermia could be a promising therapy ([Figure 1](#F1){ref-type="fig"}).
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In addition, some comparisons were made between general hypothermia and local hypothermia. In a global ischemia research study, a water-cooling blanket (the rapid infusion of cooled saline, gastric lavage with cooled saline) and sedation were used to cool the whole body. Head cooling was achieved by a cooling helmet. These two neuroprotections are similar, and whole-body cooling had a greater effect on the suppression of radical production than head cooling ([@B37]). A research study comparing selective head cooling therapy with whole body cooling therapy in newborns with hypoxic ischemic encephalopathy uncovered no difference between the two methods in terms of adverse effects and short-term results ([@B3]). Other research studies have also reached similar conclusion about hypoxic ischemic encephalopathy ([@B86],[@B87]; [@B10]). However, it was reported that local hypothermia is better than general hypothermia with a significantly lower rate of severe cortex lesions ([@B81]). It has been reported that local hypothermia may be more suitable for longer durations of hypothermia treatment for spinal cord injury because it does not require as much temperature change in healthy tissues ([@B6]). In conclusion, local hypothermia may be the best option for providing similar protection to general hypothermia and reducing temperature effects throughout the body, along with minimizing side effects. Further studies are still necessary to compare the adverse effects between local and general hypothermia and reach a definitive conclusion.

Hypothermia Combined With Other Neuroprotective Methods
=======================================================

In addition to hypothermia neuroprotection, there are other treatments that are applied to nerve injury. However, the combination of hypothermia and other treatments was found to produce a greater neuroprotective effect. These therapies are divided into three categories: cell therapy ([Table 1](#T1){ref-type="table"}), drug therapy ([Table 2](#T2){ref-type="table"}), and other therapies ([Table 3](#T3){ref-type="table"}).

###### 

The combination of hypothermia and cell therapy.

  Combination strategy                                                                                                 Model                                               Diseases                          References
  -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------- ------------
  Neural stem cells transplantation                                                                                    Spinal cord injury rat model                        Spinal cord injury                [@B126]
  Cell-scaffold complex seeded with Nogo receptor (NgR)-silenced neural stem cells and Schwann cells transplantation   Spinal cord injury rat model                        Spinal cord injury                [@B102]
  Neural stem cells transplantation                                                                                    Carotid artery ligation rat model                   Hypoxic-ischemic encephalopathy   [@B103]
  Mesenchymal stem cells transplantation                                                                               Carotid artery ligation rat model                   Hypoxic-ischemic encephalopathy   [@B74]
  Mesenchymal stem cells transplantation                                                                               Lateral fluid percussion brain injury rat model     Traumatic brain injury            [@B96]
  Adipose-derived stem cells transplantation                                                                           Middle cerebral artery occlusion (MCAO) rat model   Stroke                            [@B122]

###### 

The combination of hypothermia and drug therapy.

  Combination strategy                                                                     Model                                                                       Diseases                                        References
  ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------- ----------------
  i.v. 1 mg/kg (0.2 m L/kg) of Cannabidiol                                                 Carotid artery ligation rat model                                           Hypoxic-ischemic encephalopathy                 [@B48]
  i.p. 2.5 mg/kg of bumetanide                                                             Carotid artery ligation rat model                                           Hypoxic-ischemic encephalopathy                 [@B59]
  i.p. 0.05 ml/10 gm of Docosahexaenoic Acid (DHA)                                         Carotid artery ligation rat model                                           Hypoxic-ischemic encephalopathy                 [@B8]
  i.v. 0.0016 PNAU/100 g human urinary kallidinogenase                                     Carotid artery ligation rat model                                           Hypoxic-ischemic encephalopathy                 [@B24]
  i.p. 40 mg/kg of phenobarbital                                                           Carotid artery ligation rat model                                           Hypoxic-ischemic encephalopathy                 [@B5]
  p.o. 0.5 mg/g exendin-4                                                                  Carotid artery ligation mouse model                                         Hypoxic-ischemic encephalopathy                 [@B79]
  i.p. 20 mg/kg of topiramate or memantine/ 0.01--1 μM topiramate and 1--30 μM memantine   Carotid artery ligation rat model/OGD organotypic hippocampal slice model   Hypoxic-ischemic encephalopathy                 [@B79]
  i.v. 200 IU/kg of erythropoietin                                                         Clinical patients                                                           Hypoxic-ischemic encephalopathy                 [@B61]
  s.c. 15 mg/kg of G-CSF                                                                   MCAO rat model                                                              Stroke                                          [@B26]
  p.o. 1 mg/kg of atorvastatin                                                             MCAO rat model                                                              Stroke                                          [@B52]
  i.p. 10 mg/kg of HPI 201                                                                 MCAO rat model                                                              Stroke                                          [@B51]
  i.v. 1 mg/kg of chlorpromazine and 1 mg/kg of promethazine                               MCAO rat model                                                              Stroke                                          [@B57]
  i.v. 300 mg/kg of valproic acid                                                          Cardiac arrest rat model                                                    Cardiac arrest                                  [@B69]
  i.v. 4 ml/kg of Emulsified isoflurane (EIso)                                             Cardiac arrest rat model                                                    Cardiac arrest                                  [@B110]
  i.v. 3 mg/kg of tacrolimus                                                               Lateral fluid percussion brain injury rat model                             Traumatic brain injury                          [@B68]
  1 mmol/L VPA                                                                             Cobalt chloride (Co Cl~2~) induced -hypoxia cell model                      Cerebral ischemic and traumatic brain injury.   [@B40]
  i.p. 400 mg/kg of citicoline                                                             MCAO rat model                                                              Cerebral ischemic                               [@B83]
  Infusion, 5 mg/kg of melatonin                                                           Perinatal asphyxia piglet model                                             Hypoxic-ischemic encephalopathy                 [@B77]; [@B78]
  Infusion,1 mg/kg HET0016                                                                 Asphyxia piglet model                                                       Hypoxic-ischemic encephalopathy                 [@B126]
  40 μM dantrolene                                                                         OGD/R cell model                                                            Stroke                                          [@B112]
  100 nM C5a RA                                                                            OGD/R cell model                                                            Stroke                                          [@B95]

###### 

The combination of hypothermia and other therapies.

  Combination strategy                                                                                                    Model                                              Diseases                          References
  ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- --------------------------------- ------------
  Xenon                                                                                                                   Carotid artery ligation rat model/OGD cell model   Hypoxic-ischemic encephalopathy   [@B62]
  Intravenous loading dose of 360 μmol/kg MgSO~4~ before ischemia followed by intravenous infusion (IVI) at 120 μmol/kg   2 vessel occlusion with hypotension rat model      Stroke                            [@B125]
  Bloodletting at Jing points                                                                                             Cortical contusion injury rat model                Traumatic brain injury            [@B97]

For cell therapy, stem cells are differentiated into a variety of cells within the nervous system in order to be used for the treatment of nerve diseases. Wang and coworkers found that combination treatment with therapeutic hypothermia produced synergistic effects in transplantation to promote the recovery of spinal cord injury ([@B102]; [@B126]), while in hypoxic-ischemic encephalopathy, it was found to exert simple neuroprotective effects ([@B103]). On neonatal hypoxia-ischemic encephalopathy, mesenchymal stem cells transplantation combined treatment with hypothermia proved to be a better therapy than either therapy alone ([@B74]). Furthermore, the temperature-sensitive mesenchymal stem cells from an umbilical cord, infected with a retrovirus carrying the temperature-sensitive A58 SV40 LT antigen gene, were applied to the traumatic brain injury. In this study, the greatest protective effect on the recovery of neurological function was the therapy which combined temperature-sensitive mesenchymal stem cells and hypothermia ([@B96]). Additionally, for treating stroke, adipose-derived stem cells combined with hypothermia produced a superior approach ([@B122]). Moreover, many drugs enhanced therapeutic hypothermia neuroprotection in nerve injury. They included chemical drugs, hormones, neuroprotectants and others. For example, valproic acid is a histone deacetylase inhibitor. [@B40] showed that the combined treatment with valproic acid and hypothermia improves survival and decreases cell death after chemically induced hypoxia in HT22 hippocampal cells. Valproic acid also enhanced neuroprotective effect of hypothermia against ethanol-mediated neuronal injury, and improved survival in a rat cardiac arrest model ([@B69]; [@B100]). Bumetanide, a clinically available loop diuretic, inhibited NKCC1 and improved the neuroprotective efficacy of treatment with phenobarbital and hypothermia in a neonatal cerebral hypoxia-ischemia model ([@B59]). Cannabidiol (CBD), the main non-psychoactive component of *Cannabis sativa*, has recently been shown to produce additive effect with hypothermia, resulting in a greater overall benefit in the early HI brain damage ([@B48]). Combined emulsified isoflurane and hypothermia treatment results in significant improvements in survival and neurological outcomes in a rat model of cardiac arrest ([@B110]). Dantrolene enhances the protective effect of hypothermia on OGH/R cerebral cortex neurons ([@B112]). Early post-hypoxia-ischemia administration of phenobarbital may augment the neuroprotective efficacy of therapeutic hypothermia ([@B5]) and some hormones have a neuroprotective effect in augmenting hypothermia protection. Melatonin augmented hypothermic neuroprotection in a piglet model of perinatal asphyxia ([@B77]). Exendin-4 is an analog of the human glucagon-like peptide-1 (GLP-1) gut hormone peptide. In a study by [@B79], exendin-4 was found to enhance the neuroprotection of therapeutic hypothermia. The combined therapy with human urinary kallidinogenase (HUK) and hypothermia enhanced the efficiency by promoting angiogenesis and regeneration and rescuing tight-junction loss in HIE rat model ([@B24]). And for erythropoietin, no significant benefit was observed from treatment with combination therapy in HIE rat experiments ([@B22]). However, erythropoietin combined with hypothermia reduced serum Tau protein levels and improved neonatal behavioral neurology outcomes but did not affect long-term neurodevelopmental outcomes in neonatal patients ([@B61]). Neuroprotectants, such as G-CSF, were used in brain injury. Hypothermic treatment plus G-CSF significantly reduced mortality rate and edema and improved neurological function in the rat transient middle cerebral artery occlusion (MCAO) model ([@B26]). Atorvastatin enhances hypothermia-induced neuroprotection after stroke ([@B52]). And in a study by [@B25], a series of neuroprotectants including albumin, atorvastatin, baclofen, brain-derived neurotrophic factor, bumetanide, citicoline sodium salt hydrate, cyclosporine A etc., were applied to a oxygen-glucose deprivation and re-oxygenation-mediated neuronal injury. This research showed that combination of therapeutic hypothermia with brain derived neurotrophic factor, glibenclamide, dizocilpine, HUK or neuroglobin provided a better protection compared with a single treatment method. There are some other drugs like chlorpromazine, promethazine, citicoline and HET0016, which also augment therapeutic hypothermia protection ([@B83]; [@B57]; [@B126]). Furthermore, xenon, MgSO~4~ and Chinese traditional bloodletting treatment also offered better neuroprotection when combined with hypothermia ([@B62]; [@B125]; [@B97]).

Most of these combined treatments are confirmed to be more effective than any other treatment being used alone. They can play their therapeutic role via many ways, such as scavenging free radicals, reducing energy consumption, reducing excitotoxicity and so on ([@B120]). However, there is no denying that some combined treatments did not exhibit a synergistic effect, such as that argon augmented therapeutic hypothermia which does not improve functional recovery in cardiac arrest, but may even worsen neurologic function. These findings suggest that future studies are warranted to investigate more specific mechanisms and modulating factors in neuroprotection.

Mechanisms of Hypothermia-Mediated Protection
=============================================

Therapeutic hypothermia is a promising neuroprotective intervention which has been shown to improve outcomes from nerve injury in humans. The neuroprotective role of hypothermia has been well established in experimental animals and in patients with cardiac arrest ([@B30]), hypoxic-ischemic encephalopathy ([@B118]), traumatic brain injury ([@B53]) and other diseases ([@B126]). Although the neuroprotective mechanisms of hypothermia in different diseases vary and have yet to be fully determined, the neuroprotection has been commonly ascribe to its effect on decreasing the metabolic rate, reducing the generation of radicals, ameliorating inflammation, inhibiting excitotoxicity and apoptosis.

Hypothermia decreases the metabolic rate of neurons after spinal cord injury, traumatic brain injury and other diseases. Metabolic changes associated with hypothermia include preserving glucose ([@B88]), inhibited lactate generation ([@B17]), increased plasma levels of glycerol ([@B107]), free fatty acids and ketoacids ([@B2]). These metabolic changes induced by hypothermia are beneficial to preservation of pH and ATP of tissue and cell which promotes homeostasis ([@B46]).

The generation of free radicals and nitric oxide is considered to be associated with neuron damage ([@B54]). Hypothermia, however, significantly inhibits superoxide and lipid peroxidation to decrease the generation of free radicals. Hypothermia was found to decrease the levels of ROS induced by ischemic stroke ([@B25]) and suppress the elevation in internal jugular NO after cerebral ischemia-reperfusion ([@B47]).

Inflammation is involved in the occurrence and development of diseases, such as, cerebral ischemic injury. Further, hypothermia modulates inflammatory factors to reduce the inflammatory response. In acute brain injury, complement activation stimulates neutrophil pathways. Pro-inflammatory cytokines, including IL-1β, IL-6, IL-18, and TNF, are increased, which exacerbate neuronal injury ([@B33]; [@B66]). Hypothermia has been shown to decrease the pro-inflammatory cytokines and increase anti-inflammatory cytokines production to inhibit inflammatory response ([@B101]; [@B115]; [@B32]). However, anti-inflammatory cytokines such as IL-10 can also be reduced by hypothermia ([@B34]). It, therefore, appears that hypothermia may have a complex role in inflammatory modulation to protect neurons, that still needs to be elucidated.

Hypothermia also provides a neuroprotective benefit by decreasing excitotoxicity. The accumulation of excitotoxic amino acids, such as glutamate, is proven important in the pathogenesis of neuron damage ([@B19]; [@B13]; [@B72]; [@B84]; [@B64]). It has been reported that hypothermia inhibits the release of glutamate in a rat spinal cord ischemia model ([@B38]). [@B27] demonstrated that hypothermia reduces the extent of neuronal damage in traumatic brain injury by decreasing excessive extracellular release of glutamate and generation of hydroxyl radicals. Hypothermia reduced the release of glutamate by down-regulating the AMPA (α-amino-3-hydroxy-5-methy1-4-isoxazole-propinoic acid) to limit calcium influx and up-regulating the human glial glutamate transporter (hGLT-1).

In addition to the above mechanisms, hypothermia also works by inhibiting neuron cell apoptosis. Mild hypothermia can interfere with the intrinsic and extrinsic cell apoptosis. Intrinsic cell apoptosis is associated with caspase family of apoptosis mediators. Neuron cell injury signals promote translocation of pro-apoptotic protein Bax and Bid from cytosol to the mitochondrial membrane changing the mitochondrial membrane potential and releasing cytochrome-c and apoptosis inducing factor (AIF) ([@B76]; [@B116]; [@B90]). Then, cytochrome-c activates caspase-9 and caspase-3, leading to cell apoptosis ([@B124]; [@B70]; [@B71]). Extrinsic cell apoptosis is mediated by Fas/FasL. Increased Fas activates caspase-8, resulting in cell apoptosis ([@B58]; [@B21]). Mild hypothermia increases Bcl-2, reduces cytochrome c release, inhibits the expression of BAX and decreases caspase family members such as caspase-9, caspase-8, and caspase-3 ([@B124]; [@B70]; [@B71]; [@B94]). Mild hypothermia also inhibits the expression of matrix metalloproteinases (MMPs) to affect FasL ([@B50]), eventually leading to reduced Fas and caspase-8 ([@B58]; [Figure 2](#F2){ref-type="fig"}).
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Cold Induced Protein
====================

Although the key mechanisms have not been established clearly, cold induced proteins may play a key role in hypothermia neuroprotection, which suggests their targeting as novel therapeutic drug targets. Plenty of studies have uncovered a neuroprotective effect, focusing on these proteins. Cold-inducible RNA-binding protein (Cirbp) and cold-inducible RNA-binding protein motif 3 (RBM3) are the most widely studied proteins in this respect.

Cirbp, discovered in 1997, is a RNA-binding factor composed of a N-terminal RNA Recognition Motif (RRM) and a C-terminal region containing several repeats of the RGG motif ([@B127]). This protein is detected in low-level expression in human pancreas, heart, thyroid and other cells ([@B67]). [@B113] detected the expression of this protein in brains, lungs, stomachs and spinal cords of rats. When the temperature drops, expression levels of Cirbp are increased in PC12, K562, NC65 and other cell lines, and the expression of Cirbp in cells is decreased when the temperature is increased. Besides, in TNF-α-induced mouse fibroblast cells, hypothermia inhibited the apoptosis, and Cirbp levels were increased ([@B85]). Further, overexpression of Cirbp or application of recombinant Cirbp have shown protection against cell apoptosis ([@B56]; [@B104]). In addition, knocking down Cirbp, with shRNA-Cirbp, blocked neuroprotection under hypothermic conditions in H~2~O~2~-induced apoptosis and caspase-dependent neuron apoptosis ([@B59]; [@B104]). All these observations reveal that Cirbp is involved in the protection of tissues and organs by hypothermia. The RRM and repeats of RGG motif enhance binding of Cirbp to the 3′ UTR of TRX mRNA, resulting in enhanced expression of TRX in cells ([@B117]). TRX is a well-known ROS scavenger ([@B73]; [@B82]), and Since ROS plays a crucial role in initiating caspase-dependent pathways through induction of TRX, Cirbp may suppress intrinsic cell death mainly through TRX. Furthermore, it has been demonstrated that caspase-dependent apoptosis protein Bax, caspase-3 and caspase-9 are inhibited, and anti-apoptotic protein Bcl-2 upregulated in the rat brain cortex neurons, through upregulation of Cirbp ([@B104]). [@B111] uncovered that Bcl-2 was upregulated and Cirbp was overexpressed in BALB/c mouse testicles. Also, cirbp inhibits DNA damage-induced apoptosis by downregulating caspase-3 ([@B49]). These studies indicate Cirbp to be a regulator of caspase-dependent apoptosis pathway, in which overexpression of Cirbp can downregulate caspase-3 and other apoptosis-related proteins, while knockdown of Cirbp exacerbates these proteins expression. In addition, the level of phosphorylated extracellular signal-regulated kinase1/2 (ERK1/2) upregulation was observed in H~2~O~2~ and TNF-α-induced cell death ([@B85]; [@B56]) and the protection of hypothermia was weakened when an ERK inhibitor was used ([@B85]). Moreover, increased NF-κB activity was observed with upregulating Cirbp, when mice were exposed to lower temperatures ([@B85]; [@B42]). These data suggest that Cirbp protects cells from apoptosis partly through activating the NF-κB signaling. However, the mechanism of Cirbp in hypothermia protection is still unclear and needs more studies for a better understanding.

RBM3 is also a cold-induced protein which is induced by hypothermia ([@B16]; [@B14]) and has an impact on neuroprotection against various toxic insults such as hypoxia, UV and nitric oxide ([@B80]; [@B114]; [@B129]). One study has further discussed whether mild hypothermia and RBM3 prevents neural cells from UV irradiation-elicited apoptosis using human neuroblastoma cell line SH-SY5Y as a cell model for neural cell death ([@B129]). It was indicated that mild hypothermia protected SH-SY5Y cells from UV irradiation-induced apoptosis. However, the protective effect of mild hypothermia was abrogated when RBM3 was silenced. On the contrast, SH-SY5Y cells could be rescued from UV-induced apoptosis when RBM3 was overexpressed. Obviously, RBM3 is the key mediator of mild hypothermia-related protection against UV in neuroblastoma cells. There is also a study evaluating whether RBM3 can inhibit staurosporine-induced apoptosis in neuron-like PC12 cells ([@B11]). Mild hypothermia profoundly promoted RBM3 expression and rescued neuronal cells from apoptosis. After blocking RBM3 expression in neuronal cells by specific siRNAs, the neuroprotective effect of hypothermia was significantly diminished, and RBM3 over-expression provided neuroprotection in the absence of hypothermia. Taken together, it is apparent that RBM3 is involved in hypothermia-induced neuroprotection. Furthermore, several studies have indicated that pro-apoptotic proteins Bax, Bad, apoptotic protein PARP and caspase-3 are downregulated when the expression of RBM3 is increased under hypothermia, while the anti-apoptotic protein Bcl-2 is induced ([@B11]; [@B23]; [@B128]; [@B129]). [@B114] found that RBM3 protects neuroblastoma cells from NO-induced apoptosis by suppressing p38 signaling, which mediates apoptosis through miR-143 induction. It has been reported that RBM3 is the key mediator of mild hypothermia-related protection against UV in neuroblastoma cells, and the neuroprotective effect might be exerted through interfering with p38 and JNK pathways. Moreover, RBM3 exerts its cell-protective effects by modulating PERK-eIF2α-CHOP signaling ([@B123]). The PERK-eIF2α-CHOP signaling pathway is one of three main branches involved in unfolded protein response (UPR) activation, and it is involved in UPR-induced apoptosis ([@B31]). The effects of RBM3 on UPR-induced apoptosis have been studied. The research uncovered a hypothermia induced RBM3 expression, and that RBM3 represses the phosphorylation of PERK and eIF2α. CHOP expression was downregulated by phosphorylation of PERK and eIF2α, and EIF2α phosphorylation and CHOP protein expression were elevated in human embryonic kidney HEK293 cells by specific small interfering RNAs and in hippocampal organotypic slice cultured from RBM3 knockout mice ([@B128]). In summary, Cirbp and RBM3 have neuroprotective effects in nerve injury and may provide a potential therapeutic target for the neuroprotection.

Conclusion
==========

Hypothermia therapy has been proven neuroprotective in the patients suffering from neural injuries such as cardiac arrest and stroke, as established by many studies on the subject. However, the mechanistic aspects are not clearly understood. Clearly, more work is needed, including determination of best strategies to induce hypothermia, improving the protection and clarifying the mechanism. As discussed in this article, local hypothermia may be the best option for providing protection similar to general hypothermia and for reducing temperature effects throughout the body with minimal side effects. Several neuroprotective strategies are being tested to enhance hypothermia protection. Further, cold induced proteins are important in hypothermia protection. The discussion here should provide guidance for future animal studies and clinical trials on hypothermia neuroprotection.
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